Incretin Agonist Exenatide

The prototype GLP agonist is exenatide, which is structurally similar to GLP and was initially approved for use as the therapeutic effects of metformin and sulfonylurea diminished. Exenatide is given subcutaneously by fixed dosages of 5 or 10 ^.g, twice daily before meals. Its major side effect is nausea and a sense of non-well-being, which limits appetite and food intake. About 50% of patients are intolerant of treatment in the short term, although many adjust to the side effects, which lessen over time. Overweight patients who are able to take exenatide lose more than 10 pounds (4.5 kg) in the first year. Weight losses can be dramatic, with marked improvement in HbA1c values. Significant weight loss without HbA1c improvement in suggests that the patient has minimal insulin secretory reserve. Exenatide is a therapeutic consideration in overweight patients no longer or not responding to oral agents. Although experience combining exenatide with insulin is sparse, some clinicians report the combination of basal insulin to control fasting glucose with exenatide to be efficacious.

Diabetes 2

Diabetes 2

Diabetes is a disease that affects the way your body uses food. Normally, your body converts sugars, starches and other foods into a form of sugar called glucose. Your body uses glucose for fuel. The cells receive the glucose through the bloodstream. They then use insulin a hormone made by the pancreas to absorb the glucose, convert it into energy, and either use it or store it for later use. Learn more...

Get My Free Ebook


Post a comment